Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 14/20 | 0.38 |
| ▸ | LYPLA1 | O75608 | 1/20 | 0.33 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.33 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8957146 | 0.99 | FPR2 (0.39) | FPR2LYPLA1LYPLA2ABHD16A | |
| SCHEMBL8957301 | 0.92 | FPR2 (0.36) | FPR2ALDH1A1 | |
| SCHEMBL8956870 | 0.91 | FPR2 (0.40) | FPR2 | |
| SCHEMBL8955052 | 0.91 | FPR2 (0.35) | FPR2LYPLA1LYPLA2ABHD16ACYP3A4 | |
| SCHEMBL8957219 | 0.91 | FPR2 (0.37) | FPR2ALDH1A1TDP1 | |
| SCHEMBL8957380 | 0.91 | FPR2 (0.37) | FPR2ALDH1A1TDP1 | |
| SCHEMBL8957325 | 0.91 | FPR2 (0.37) | FPR2ALDH1A1TDP1 | |
| SCHEMBL8957200 | 0.91 | FPR2 (0.37) | FPR2ALDH1A1TDP1 | |
| SCHEMBL8957304 | 0.91 | FPR2 (0.35) | FPR2ALDH1A1 | |
| SCHEMBL8957318 | 0.91 | FPR2 (0.37) | FPR2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8187494-B2 | Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | KIF23, HCN3, FZD7 | FPR2 1427/4885LYPLA1 3903/4885LYPLA2 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.